Details for Patent: 11,072,586
✉ Email this page to a colleague
Which drugs does patent 11,072,586 protect, and when does it expire?
Patent 11,072,586 protects ALVAIZ and is included in one NDA.
This patent has two patent family members in two countries.
Summary for Patent: 11,072,586
| Title: | Solid state forms of eltrombopag choline |
| Abstract: | Solid state forms of Eltrombopag choline, processes for preparation thereof and pharmaceutical compositions thereof are disclosed. |
| Inventor(s): | Hariprasad Sharma Vijay, Shafakat Ali Nasir Ali, Vijay Joshi Ashutosh, Luthra Parven Kumar, Muthusamy Anantha Rajmohan, Singh Amit, Bate Rajesh Sadanand, Maurya Sadanand Hardeo |
| Assignee: | ASSIA CHEMICAL INDUSTRIES LTD. |
| Application Number: | US16753363 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 11,072,586
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-001 | Nov 29, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY | ⤷ Sign Up | ||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-001 | Nov 29, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY | ⤷ Sign Up | ||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-001 | Nov 29, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) | ⤷ Sign Up | ||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-002 | Nov 29, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY | ⤷ Sign Up | ||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-002 | Nov 29, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) | ⤷ Sign Up | ||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-002 | Nov 29, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,072,586
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3692021 | ⤷ Sign Up | |||
| World Intellectual Property Organization (WIPO) | 2019071111 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
